<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01206062</url>
  </required_header>
  <id_info>
    <org_study_id>SPRINT</org_study_id>
    <secondary_id>268200900040C-1-0-1</secondary_id>
    <nct_id>NCT01206062</nct_id>
  </id_info>
  <brief_title>Systolic Blood Pressure Intervention Trial</brief_title>
  <acronym>SPRINT</acronym>
  <official_title>Systolic Blood Pressure Intervention Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elevated blood pressure (BP) is an important public health concern. It is highly prevalent,
      the prevalence may be increasing, and it is a risk factor for several adverse health
      outcomes, especially coronary heart disease, stroke, heart failure, chronic kidney disease,
      and decline in cognitive function. The Systolic Blood Pressure Intervention Trial (SPRINT) is
      a 2-arm, multicenter, randomized clinical trial designed to test whether a treatment program
      aimed at reducing systolic blood pressure (SBP) to a lower goal than currently recommended
      will reduce cardiovascular disease (CVD) risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SPRINT strived to enroll about 9250 participants aged ≥ 50 years with SBP ≥130 mm Hg and at
      least one additional CVD risk factor. The trial compared the effects of randomization to a
      treatment program of an intensive SBP goal with randomization to a treatment program of a
      standard goal. Target SBP goals were &lt;120 vs &lt;140 mm Hg, respectively, to create a minimum
      mean difference of 10 mm Hg between the two randomized groups. The primary hypothesis was
      that CVD event rates would be lower in the intensive arm. Participants were recruited at
      approximately 90 clinics within 5 clinical center networks (CCNs) over approximately a 2-year
      period, and were followed for 4-6 years.

      A total of 9361 participants were enrolled. NIH stopped the blood pressure intervention
      earlier than originally planned in order to quickly disseminate the significant preliminary
      results. Follow-up for cognitive and kidney outcomes continues during the post-intervention
      phase through May 2018.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2010</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With First Occurrence of a Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Stroke, Heart Failure (HF), or CVD Death</measure>
    <time_frame>6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Mortality</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CKD Participants Who Experienced a 50% Decline From Baseline eGFR</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Developed End Stage Renal Disease</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dementia</measure>
    <time_frame>6 years</time_frame>
    <description>Additional data are being collected over the next year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline in Cognitive Function</measure>
    <time_frame>6 years</time_frame>
    <description>Additional data are being collected over the next year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small Vessel Cerebral Ischemic Disease</measure>
    <time_frame>6 years</time_frame>
    <description>Additional data are being collected over the next year.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9361</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Intensive Control of SBP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized into the Intensive BP arm will have a goal of SBP &lt;120 mm Hg. 2-drug therapy initiated in most Intensive participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP &lt;120 mm Hg; at periodic &quot;milepost&quot; visits: addition of another drug &quot;required&quot; if not at goal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Control of SBP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized into the Standard arm will have a goal of SBP &lt;140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP &lt;130 mm Hg @ 1 visit; &lt;135 mm Hg @ 2 consecutive visits</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive control of SBP</intervention_name>
    <description>Participants in the Intensive arm have a goal of SBP &lt;120 mm Hg. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:
Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics
Combination products will be available, depending on cost, utility, or donations from pharmaceutical companies.</description>
    <arm_group_label>Intensive Control of SBP</arm_group_label>
    <other_name>Lower target for SBP</other_name>
    <other_name>Comparison of standard SBP control to a target of 120 mm Hg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard control of SBP</intervention_name>
    <description>Participants in the Standard BP arm have a goal of SBP &lt;140 mm Hg. The same medications used in the Intensive BP arm will be used for the Standard BP arm.</description>
    <arm_group_label>Standard Control of SBP</arm_group_label>
    <other_name>Control of SBP to a target of 140 mm Hg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 50 years old

        Systolic blood pressure of

          -  130 - 180 mm Hg on 0 or 1 medication

          -  130 - 170 mm Hg on up to 2 medications

          -  130 - 160 mm Hg on up to 3 medications

          -  130 - 150 mm Hg on up to 4 medications

        Risk (one or more of the following)

          1. Presence of clinical or subclinical cardiovascular disease other than stroke

          2. CKD, defined as eGFR 20 - 59 ml/min/1.73m2

          3. A Framingham Risk Score for 10-year CVD risk ≥ 15%

          4. Age greater than 75 years

        Exclusion Criteria:

          -  An indication for a specific BP lowering medication that the person is not taking and
             the person has not been documented to be intolerant of the medication class.

          -  Known secondary cause of hypertension that causes concern regarding safety of the
             protocol.

          -  One minute standing SBP &lt; 110 mm Hg.

          -  Proteinuria in the following ranges (based on a measurement within the past 6 months)

               -  24 hour urinary protein excretion ≥1 g/day, or

               -  24 hour urinary albumin excretion ≥ 600 mg/day, or

               -  spot urine protein/creatinine ratio ≥ 1 g/g creatinine, or

               -  spot urine albumin/creatinine ratio ≥ 600 mg/g creatinine, or

               -  urine dipstick ≥ 2+ protein

          -  Arm circumference too large or small to allow accurate blood pressure measurement with
             available devices

          -  Diabetes mellitus,

          -  History of stroke (not CE or stenting)

          -  Diagnosis of polycystic kidney disease

          -  Glomerulonephritis treated with or likely to be treated with immunosuppressive therapy

          -  eGFR &lt; 20 ml/min /1.73m2 or end-stage renal disease (ESRD)

          -  Cardiovascular event or procedure (as defined above as clinical CVD for study entry)
             or hospitalization for unstable angina within last 3 months

          -  Symptomatic heart failure within the past 6 months or left ventricular ejection
             fraction (by any method) &lt; 35%

          -  A medical condition likely to limit survival to less than 3 years or a malignancy
             other than non-melanoma skin cancer within the last 2 years

          -  Any factors judged by the clinic team to be likely to limit adherence to
             interventions.

          -  Failure to obtain informed consent from participant

          -  Currently participating in another clinical trial (intervention study). Note: Patient
             must wait until the completion of his/her activities or the completion of the other
             trial before being screened for SPRINT.

          -  Living in the same household as an already randomized SPRINT participant

          -  Any organ transplant

          -  Unintentional weight loss &gt; 10% in last 6 months

          -  Pregnancy, currently trying to become pregnant, or of child-bearing potential and not
             using birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Reboussin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jackson T Wright, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfred Cheung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suzanne Oparil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mike Rocco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bill Cushman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memphis VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT Jr, Whelton PK; SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014 Oct;11(5):532-46. doi: 10.1177/1740774514537404. Epub 2014 Jun 5.</citation>
    <PMID>24902920</PMID>
  </reference>
  <reference>
    <citation>Ramsey TM, Snyder JK, Lovato LC, Roumie CL, Glasser SP, Cosgrove NM, Olney CM, Tang RH, Johnson KC, Still CH, Gren LH, Childs JC, Crago OL, Summerson JH, Walsh SM, Perdue LH, Bankowski DM, Goff DC; SPRINT Study Research Group. Recruitment strategies and challenges in a large intervention trial: Systolic Blood Pressure Intervention Trial. Clin Trials. 2016 Jun;13(3):319-30. doi: 10.1177/1740774516631735. Epub 2016 Feb 24.</citation>
    <PMID>26911833</PMID>
  </reference>
  <results_reference>
    <citation>SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9. Erratum in: N Engl J Med. 2017 Dec 21;377(25):2506.</citation>
    <PMID>26551272</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2010</study_first_submitted>
  <study_first_submitted_qc>September 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2010</study_first_posted>
  <results_first_submitted>July 13, 2017</results_first_submitted>
  <results_first_submitted_qc>November 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 4, 2017</results_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wake Forest University Health Sciences</investigator_affiliation>
    <investigator_full_name>David Reboussin</investigator_full_name>
    <investigator_title>Principal Investigator, Coordinating Center</investigator_title>
  </responsible_party>
  <keyword>blood pressure</keyword>
  <keyword>antihypertensive</keyword>
  <keyword>systolic</keyword>
  <keyword>diastolic</keyword>
  <keyword>heart failure</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>stroke</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>dementia</keyword>
  <keyword>cognitive decline</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intensive Control of SBP</title>
          <description>Participants randomized into the Intensive BP arm had a goal of SBP &lt;120 mm Hg. 2-drug therapy initiated in most participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP &lt;120 mm Hg; at periodic visits: addition of another drug &quot;required&quot; if not at goal.
Intensive control of SBP: Use of once-daily antihypertensive agents was encouraged unless alternative frequency was necessary. One or more medications from the following classes of agents were provided by the study for use in managing participants in both groups to achieve study goals:
Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics</description>
        </group>
        <group group_id="P2">
          <title>Standard Control of SBP</title>
          <description>Participants randomized into the Standard arm had a goal of SBP &lt;140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP &lt;130 mm Hg @ 1 visit; &lt;135 mm Hg @ 2 consecutive visits
Standard control of SBP: The same medications used in the Intensive BP arm will be used for the Standard BP arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4678"/>
                <participants group_id="P2" count="4683"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4678"/>
                <participants group_id="P2" count="4683"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intensive Control of SBP</title>
          <description>Participants randomized into the Intensive BP arm had a goal of SBP &lt;120 mm Hg. 2-drug therapy initiated in most participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP &lt;120 mm Hg; at periodic visits: addition of another drug &quot;required&quot; if not at goal.
Intensive control of SBP: Use of once-daily antihypertensive agents was encouraged unless alternative frequency was necessary. One or more medications from the following classes of agents were provided by the study for use in managing participants in both groups to achieve study goals:
Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics</description>
        </group>
        <group group_id="B2">
          <title>Standard Control of SBP</title>
          <description>Participants randomized into the Standard arm had a goal of SBP &lt;140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP &lt;130 mm Hg @ 1 visit; &lt;135 mm Hg @ 2 consecutive visits
Standard control of SBP: The same medications used in the Intensive BP arm will be used for the Standard BP arm.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4678"/>
            <count group_id="B2" value="4683"/>
            <count group_id="B3" value="9361"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.9" spread="9.4"/>
                    <measurement group_id="B2" value="67.9" spread="9.5"/>
                    <measurement group_id="B3" value="67.9" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Among those &gt;= 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.8" spread="3.9"/>
                    <measurement group_id="B2" value="79.9" spread="4.1"/>
                    <measurement group_id="B3" value="79.9" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1684"/>
                    <measurement group_id="B2" value="1648"/>
                    <measurement group_id="B3" value="3332"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2994"/>
                    <measurement group_id="B2" value="3035"/>
                    <measurement group_id="B3" value="6029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race and ethnic group were self-reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-Hispanic black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1379"/>
                    <measurement group_id="B2" value="1423"/>
                    <measurement group_id="B3" value="2802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="503"/>
                    <measurement group_id="B2" value="481"/>
                    <measurement group_id="B3" value="984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2698"/>
                    <measurement group_id="B2" value="2701"/>
                    <measurement group_id="B3" value="5399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated GFR</title>
          <units>ml/min/1.73 m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Among all participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.8" spread="20.7"/>
                    <measurement group_id="B2" value="71.7" spread="20.5"/>
                    <measurement group_id="B3" value="71.7" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Among those with estimated GFR &gt;= 60 ml/min/1.73 m</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.3" spread="15.5"/>
                    <measurement group_id="B2" value="81.1" spread="15.5"/>
                    <measurement group_id="B3" value="81.2" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Among those with estimated GFR &lt; 60 ml/min/1.73 m</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="9.5"/>
                    <measurement group_id="B2" value="47.9" spread="9.5"/>
                    <measurement group_id="B3" value="47.8" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Criterion for increased cardiovascular risk</title>
          <description>Increased cardiovascular risk was one of the inclusion criteria.
Chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 ml per minute per 1.73 m squared of body-surface area.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age &gt; 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1317"/>
                    <measurement group_id="B2" value="1319"/>
                    <measurement group_id="B3" value="2636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic kidney disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1330"/>
                    <measurement group_id="B2" value="1316"/>
                    <measurement group_id="B3" value="2646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="940"/>
                    <measurement group_id="B2" value="937"/>
                    <measurement group_id="B3" value="1877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular disease clinical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="779"/>
                    <measurement group_id="B2" value="783"/>
                    <measurement group_id="B3" value="1562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular disease subclinical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="246"/>
                    <measurement group_id="B3" value="493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Framingham CVD risk score &gt;= 15%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2870"/>
                    <measurement group_id="B2" value="2867"/>
                    <measurement group_id="B3" value="5737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Black race</title>
          <description>Black race includes Hispanic black and black as part of a multiracial identification.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1454"/>
                    <measurement group_id="B2" value="1493"/>
                    <measurement group_id="B3" value="2947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline BP mm Hg</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139.7" spread="15.8"/>
                    <measurement group_id="B2" value="139.7" spread="15.4"/>
                    <measurement group_id="B3" value="139.7" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.2" spread="11.9"/>
                    <measurement group_id="B2" value="78.0" spread="12.0"/>
                    <measurement group_id="B3" value="78.1" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Distribution of systolic blood pressure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 132 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1583"/>
                    <measurement group_id="B2" value="1553"/>
                    <measurement group_id="B3" value="3136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 132 mm Hg to &lt; 145 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1489"/>
                    <measurement group_id="B2" value="1549"/>
                    <measurement group_id="B3" value="3038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 145 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1606"/>
                    <measurement group_id="B2" value="1581"/>
                    <measurement group_id="B3" value="3187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum creatinine</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.07" spread="0.34"/>
                    <measurement group_id="B2" value="1.08" spread="0.34"/>
                    <measurement group_id="B3" value="1.07" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ratio of urinary albumin (mg) to creatinine (g)</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.1" spread="178.7"/>
                    <measurement group_id="B2" value="41.1" spread="152.9"/>
                    <measurement group_id="B3" value="42.6" spread="166.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting total cholesterol - mg/dl</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190.2" spread="41.4"/>
                    <measurement group_id="B2" value="190.0" spread="40.9"/>
                    <measurement group_id="B3" value="190.1" spread="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting HDL cholesterol - mg/dl</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.9" spread="14.3"/>
                    <measurement group_id="B2" value="52.8" spread="14.6"/>
                    <measurement group_id="B3" value="52.9" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting total triglycerides — mg/dl</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124.8" spread="85.8"/>
                    <measurement group_id="B2" value="127.1" spread="95.0"/>
                    <measurement group_id="B3" value="125.9" spread="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose — mg/dl</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98.8" spread="13.7"/>
                    <measurement group_id="B2" value="98.8" spread="13.4"/>
                    <measurement group_id="B3" value="98.8" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Statin use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Statin Use</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1978"/>
                    <measurement group_id="B2" value="2076"/>
                    <measurement group_id="B3" value="4054"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Statin Use</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2667"/>
                    <measurement group_id="B2" value="2564"/>
                    <measurement group_id="B3" value="5231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown Statin Use</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspirin use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Aspirin Use</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2406"/>
                    <measurement group_id="B2" value="2350"/>
                    <measurement group_id="B3" value="4756"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Aspirin Use</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2255"/>
                    <measurement group_id="B2" value="2316"/>
                    <measurement group_id="B3" value="4571"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown Aspirin Use</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking status — no. (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2050"/>
                    <measurement group_id="B2" value="2072"/>
                    <measurement group_id="B3" value="4122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1977"/>
                    <measurement group_id="B2" value="1996"/>
                    <measurement group_id="B3" value="3973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="639"/>
                    <measurement group_id="B2" value="601"/>
                    <measurement group_id="B3" value="1240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Framingham 10-yr cardiovascular disease risk score</title>
          <description>The Framingham Risk Score is a gender-specific algorithm used to estimate the 10-year cardiovascular risk of an individual. It presents risk as the probability of developing coronary heart disease (CHD) within the next 10 years. Individuals with low risk have 10% or less CHD risk at 10 years, with intermediate risk 10-20%, and with high risk 20% or more.</description>
          <units>probability</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.8" spread="12.6"/>
                    <measurement group_id="B2" value="24.8" spread="12.5"/>
                    <measurement group_id="B3" value="24.8" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body-mass index</title>
          <description>The body-mass index is the weight in kilograms divided by the square of the height in meters.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.9" spread="5.8"/>
                    <measurement group_id="B2" value="29.8" spread="5.7"/>
                    <measurement group_id="B3" value="29.9" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antihypertensive agents — no./patient</title>
          <units>agents per patient</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="1.0"/>
                    <measurement group_id="B2" value="1.8" spread="1.0"/>
                    <measurement group_id="B3" value="1.8" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Not using antihypertensive agents — no. (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="432"/>
                    <measurement group_id="B2" value="450"/>
                    <measurement group_id="B3" value="882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With First Occurrence of a Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Stroke, Heart Failure (HF), or CVD Death</title>
        <time_frame>6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive Control of SBP</title>
            <description>Participants randomized into the Intensive BP arm had a goal of SBP &lt;120 mm Hg. 2-drug therapy initiated in most participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP &lt;120 mm Hg; at periodic visits: addition of another drug &quot;required&quot; if not at goal.
Intensive control of SBP: Use of once-daily antihypertensive agents was encouraged unless alternative frequency was necessary. One or more medications from the following classes of agents were provided by the study for use in managing participants in both groups to achieve study goals:
Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics</description>
          </group>
          <group group_id="O2">
            <title>Standard Control of SBP</title>
            <description>Participants randomized into the Standard arm had a goal of SBP &lt;140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP &lt;130 mm Hg @ 1 visit; &lt;135 mm Hg @ 2 consecutive visits
Standard control of SBP: The same medications used in the Intensive BP arm will be used for the Standard BP arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of a Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Stroke, Heart Failure (HF), or CVD Death</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4678"/>
                <count group_id="O2" value="4683"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243"/>
                    <measurement group_id="O2" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Mortality</title>
        <time_frame>6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive Control of SBP</title>
            <description>Participants randomized into the Intensive BP arm had a goal of SBP &lt;120 mm Hg. 2-drug therapy initiated in most participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP &lt;120 mm Hg; at periodic visits: addition of another drug &quot;required&quot; if not at goal.
Intensive control of SBP: Use of once-daily antihypertensive agents was encouraged unless alternative frequency was necessary. One or more medications from the following classes of agents were provided by the study for use in managing participants in both groups to achieve study goals:
Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics</description>
          </group>
          <group group_id="O2">
            <title>Standard Control of SBP</title>
            <description>Participants randomized into the Standard arm had a goal of SBP &lt;140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP &lt;130 mm Hg @ 1 visit; &lt;135 mm Hg @ 2 consecutive visits
Standard control of SBP: The same medications used in the Intensive BP arm will be used for the Standard BP arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4678"/>
                <count group_id="O2" value="4683"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of CKD Participants Who Experienced a 50% Decline From Baseline eGFR</title>
        <time_frame>6 years</time_frame>
        <population>Participants with CKD at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Intensive Control of SBP</title>
            <description>Participants randomized into the Intensive BP arm had a goal of SBP &lt;120 mm Hg. 2-drug therapy initiated in most participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP &lt;120 mm Hg; at periodic visits: addition of another drug &quot;required&quot; if not at goal.
Intensive control of SBP: Use of once-daily antihypertensive agents was encouraged unless alternative frequency was necessary. One or more medications from the following classes of agents were provided by the study for use in managing participants in both groups to achieve study goals:
Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics</description>
          </group>
          <group group_id="O2">
            <title>Standard Control of SBP</title>
            <description>Participants randomized into the Standard arm had a goal of SBP &lt;140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP &lt;130 mm Hg @ 1 visit; &lt;135 mm Hg @ 2 consecutive visits
Standard control of SBP: The same medications used in the Intensive BP arm will be used for the Standard BP arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CKD Participants Who Experienced a 50% Decline From Baseline eGFR</title>
          <population>Participants with CKD at baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1330"/>
                <count group_id="O2" value="1316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Developed End Stage Renal Disease</title>
        <time_frame>6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intensive Control of SBP</title>
            <description>Participants randomized into the Intensive BP arm had a goal of SBP &lt;120 mm Hg. 2-drug therapy initiated in most participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP &lt;120 mm Hg; at periodic visits: addition of another drug &quot;required&quot; if not at goal.
Intensive control of SBP: Use of once-daily antihypertensive agents was encouraged unless alternative frequency was necessary. One or more medications from the following classes of agents were provided by the study for use in managing participants in both groups to achieve study goals:
Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics</description>
          </group>
          <group group_id="O2">
            <title>Standard Control of SBP</title>
            <description>Participants randomized into the Standard arm had a goal of SBP &lt;140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP &lt;130 mm Hg @ 1 visit; &lt;135 mm Hg @ 2 consecutive visits
Standard control of SBP: The same medications used in the Intensive BP arm will be used for the Standard BP arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Developed End Stage Renal Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4678"/>
                <count group_id="O2" value="4683"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dementia</title>
        <description>Additional data are being collected over the next year.</description>
        <time_frame>6 years</time_frame>
        <posting_date>05/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decline in Cognitive Function</title>
        <description>Additional data are being collected over the next year.</description>
        <time_frame>6 years</time_frame>
        <posting_date>05/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Small Vessel Cerebral Ischemic Disease</title>
        <description>Additional data are being collected over the next year.</description>
        <time_frame>6 years</time_frame>
        <posting_date>05/2018</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Includes Serious Adverse Events (SAEs) reported after randomization and throughout the duration of the trial, mean follow-up was 3.26 years.</time_frame>
      <desc>Adverse event reporting included occurrence of acute kidney injury or acute renal failure and specific monitored conditions if they were evaluated in emergency departments (hypotension, syncope, injurious falls, electrolyte abnormalities, bradycardia).</desc>
      <group_list>
        <group group_id="E1">
          <title>Intensive Control of SBP</title>
          <description>Participants randomized into the Intensive BP arm had a goal of SBP &lt;120 mm Hg. 2-drug therapy initiated in most participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP &lt;120 mm Hg; at periodic visits: addition of another drug &quot;required&quot; if not at goal.
Intensive control of SBP: Use of once-daily antihypertensive agents was encouraged unless alternative frequency was necessary. One or more medications from the following classes of agents were provided by the study for use in managing participants in both groups to achieve study goals:
Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics</description>
        </group>
        <group group_id="E2">
          <title>Standard Control of SBP</title>
          <description>Participants randomized into the Standard arm had a goal of SBP &lt;140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP &lt;130 mm Hg @ 1 visit; &lt;135 mm Hg @ 2 consecutive visits
Standard control of SBP: The same medications used in the Intensive BP arm will be used for the Standard BP arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="210" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1793" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="1736" subjects_at_risk="4683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="191" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Other ischaemic heart disease</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Myocardial infarcation</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="4683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="210" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>Occurred in less than 1% of total adverse events</description>
                <counts group_id="E1" subjects_affected="952" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="951" subjects_at_risk="4683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="4683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="4683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="4683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="4683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="4683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic cerebrovascular conditions</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="4683"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1399" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="1342" subjects_at_risk="4683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="4683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte Abnormality</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Injurious fall</sub_title>
                <counts group_id="E1" subjects_affected="229" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="222" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Serum sodium &lt; 130 mmol/liter</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Serum sodium &gt; 150 mmol/liter</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Serum potassium &lt;3.0 mmol/liter</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Serum potassium &gt;5.5 mmol/liter</sub_title>
                <counts group_id="E1" subjects_affected="176" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="4683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension alone</sub_title>
                <counts group_id="E1" subjects_affected="777" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="857" subjects_at_risk="4683"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension with dizziness</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="4683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury or acute renal failure</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4683"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="4678"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="4683"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Reboussin</name_or_title>
      <organization>Wake Forest University Health Sciences</organization>
      <phone>336-716-6844</phone>
      <email>drebouss@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

